Cyclosporine A, alpha-interferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: A phase II study in advanced melanoma

Lynn G Feun, Angela Marini, Frederick L Moffat, Niramol Savaraj, Judith Hurley, Amitabha Mazumder

Research output: Contribution to journalArticle

Abstract

Preclinical data suggest that one method of inducing autoimmunity to tumor is the administration and subsequent withdrawal of cyclosporine A following chemotherapy and that this effect may be enhanced with interferon and interleukin-2. Consequently, we performed a phase II trial in patients with advanced melanoma to explore this approach. Thirty-three patients were treated with BCNU (150 mg/m2 iv every 8 weeks), cisplatin (25 mg/m 2 iv days 1-3) every 4 weeks, DTIC (220 mg/m2 iv days 1-3 every 4 weeks) along with tamoxifen (10 mg po BID days 1-4). Cyclosporine A at 3 mg/kg/day in two divided doses was given on days 4-21, alpha-interferon 1 million units/m2 subcutaneously every other day on days 4-21 and interleukin-2 1 million units/m2 BID subcutaneously days 21-28 were also given. Of the 33 patients, 3 patients (9%) had complete response and 8 patients (24%) had a partial response for a total response rate of 33% (95% confidence interval 18-52%). Median duration of response was 17 months (range 3+ to 24+ months). Six patients continue to show no signs of tumor progression for 3+, 5+, 10+, 24+, 60+, and 72+ months. Toxicity was generally well tolerated and included myelosuppression and fatigue. This regimen is feasible and generally tolerable and has produced an antitumor response rate comparable with inpatient biochemotherapy regimens.

Original languageEnglish
Pages (from-to)3-8
Number of pages6
JournalCancer Investigation
Volume23
Issue number1
DOIs
StatePublished - Mar 21 2005

Fingerprint

Carmustine
Dacarbazine
Tamoxifen
Interferon-alpha
Cisplatin
Cyclosporine
Interleukin-2
Melanoma
Drug Therapy
Autoimmunity
Interleukin-1
Interferons
Fatigue
Inpatients
Neoplasms
Confidence Intervals

Keywords

  • Cyclosporine
  • Interferon
  • Interleukin
  • Melanoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{dd9f523c09124dacb926ef49a51e213b,
title = "Cyclosporine A, alpha-interferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: A phase II study in advanced melanoma",
abstract = "Preclinical data suggest that one method of inducing autoimmunity to tumor is the administration and subsequent withdrawal of cyclosporine A following chemotherapy and that this effect may be enhanced with interferon and interleukin-2. Consequently, we performed a phase II trial in patients with advanced melanoma to explore this approach. Thirty-three patients were treated with BCNU (150 mg/m2 iv every 8 weeks), cisplatin (25 mg/m 2 iv days 1-3) every 4 weeks, DTIC (220 mg/m2 iv days 1-3 every 4 weeks) along with tamoxifen (10 mg po BID days 1-4). Cyclosporine A at 3 mg/kg/day in two divided doses was given on days 4-21, alpha-interferon 1 million units/m2 subcutaneously every other day on days 4-21 and interleukin-2 1 million units/m2 BID subcutaneously days 21-28 were also given. Of the 33 patients, 3 patients (9{\%}) had complete response and 8 patients (24{\%}) had a partial response for a total response rate of 33{\%} (95{\%} confidence interval 18-52{\%}). Median duration of response was 17 months (range 3+ to 24+ months). Six patients continue to show no signs of tumor progression for 3+, 5+, 10+, 24+, 60+, and 72+ months. Toxicity was generally well tolerated and included myelosuppression and fatigue. This regimen is feasible and generally tolerable and has produced an antitumor response rate comparable with inpatient biochemotherapy regimens.",
keywords = "Cyclosporine, Interferon, Interleukin, Melanoma",
author = "Feun, {Lynn G} and Angela Marini and Moffat, {Frederick L} and Niramol Savaraj and Judith Hurley and Amitabha Mazumder",
year = "2005",
month = "3",
day = "21",
doi = "10.1081/CNV-200046368",
language = "English",
volume = "23",
pages = "3--8",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Cyclosporine A, alpha-interferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen

T2 - A phase II study in advanced melanoma

AU - Feun, Lynn G

AU - Marini, Angela

AU - Moffat, Frederick L

AU - Savaraj, Niramol

AU - Hurley, Judith

AU - Mazumder, Amitabha

PY - 2005/3/21

Y1 - 2005/3/21

N2 - Preclinical data suggest that one method of inducing autoimmunity to tumor is the administration and subsequent withdrawal of cyclosporine A following chemotherapy and that this effect may be enhanced with interferon and interleukin-2. Consequently, we performed a phase II trial in patients with advanced melanoma to explore this approach. Thirty-three patients were treated with BCNU (150 mg/m2 iv every 8 weeks), cisplatin (25 mg/m 2 iv days 1-3) every 4 weeks, DTIC (220 mg/m2 iv days 1-3 every 4 weeks) along with tamoxifen (10 mg po BID days 1-4). Cyclosporine A at 3 mg/kg/day in two divided doses was given on days 4-21, alpha-interferon 1 million units/m2 subcutaneously every other day on days 4-21 and interleukin-2 1 million units/m2 BID subcutaneously days 21-28 were also given. Of the 33 patients, 3 patients (9%) had complete response and 8 patients (24%) had a partial response for a total response rate of 33% (95% confidence interval 18-52%). Median duration of response was 17 months (range 3+ to 24+ months). Six patients continue to show no signs of tumor progression for 3+, 5+, 10+, 24+, 60+, and 72+ months. Toxicity was generally well tolerated and included myelosuppression and fatigue. This regimen is feasible and generally tolerable and has produced an antitumor response rate comparable with inpatient biochemotherapy regimens.

AB - Preclinical data suggest that one method of inducing autoimmunity to tumor is the administration and subsequent withdrawal of cyclosporine A following chemotherapy and that this effect may be enhanced with interferon and interleukin-2. Consequently, we performed a phase II trial in patients with advanced melanoma to explore this approach. Thirty-three patients were treated with BCNU (150 mg/m2 iv every 8 weeks), cisplatin (25 mg/m 2 iv days 1-3) every 4 weeks, DTIC (220 mg/m2 iv days 1-3 every 4 weeks) along with tamoxifen (10 mg po BID days 1-4). Cyclosporine A at 3 mg/kg/day in two divided doses was given on days 4-21, alpha-interferon 1 million units/m2 subcutaneously every other day on days 4-21 and interleukin-2 1 million units/m2 BID subcutaneously days 21-28 were also given. Of the 33 patients, 3 patients (9%) had complete response and 8 patients (24%) had a partial response for a total response rate of 33% (95% confidence interval 18-52%). Median duration of response was 17 months (range 3+ to 24+ months). Six patients continue to show no signs of tumor progression for 3+, 5+, 10+, 24+, 60+, and 72+ months. Toxicity was generally well tolerated and included myelosuppression and fatigue. This regimen is feasible and generally tolerable and has produced an antitumor response rate comparable with inpatient biochemotherapy regimens.

KW - Cyclosporine

KW - Interferon

KW - Interleukin

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=14844304333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14844304333&partnerID=8YFLogxK

U2 - 10.1081/CNV-200046368

DO - 10.1081/CNV-200046368

M3 - Article

C2 - 15779861

VL - 23

SP - 3

EP - 8

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 1

ER -